Becton Dickinson Issues €600 Million 3.855% Notes Due 2033 to Refinance 2026 Debt

Becton, Dickinson and Company (BDX) has recently lagged the healthcare sector, while rival Intuitive Surgical (ISRG) has fallen 26.2% over 52 weeks and 28.1% year-to-date, according to the article. Despite BDX’s underperformance, 14 analysts rate it “Moderate Buy,” with a mean $175.75 price target, implying a 20.7% premium.

The article highlights Dividend Kings, focusing on PepsiCo and Becton Dickinson. It says PepsiCo has raised its dividend for 54 straight years, with a ~3.9% yield and a recent ~4% increase, and notes organic revenue growth of 1%–3% per quarter. For Becton Dickinson, it cites 53 years of dividend growth, a ~2.8% yield, and fiscal 2026 guidance of EPS $14.75–$15.05 (midpoint) and low single-digit revenue growth.

Hinde Group released its Q1 2026 investor letter, reporting gross return of 3.80% and net return of 3.41% versus -4.33% for the S&P 500, citing market volatility tied to Iran-related conflict. The firm highlighted Becton, Dickinson and Company (BDX), noting a July 2025 position and that BD completed a Reverse Morris Trust with Waters on Feb. 9, receiving $4B cash and Waters shares.

The article highlights three “blue chip” stocks it says look attractively priced after a market pullback: Microsoft (MSFT), Becton Dickinson (BDX), and Clorox (CLX). It cites MSFT’s forward P/E of 22 and ~0.83% dividend yield; BDX’s forward P/E of 11.7 and ~2.36% yield; and CLX’s forward P/E of 13 and ~5.16% yield, noting oil costs of over $20M quarterly gross profit.

BD (Becton, Dickinson and Company) has launched the Elyra™ Thulium Fiber Laser (TFL) System, designed to enhance kidney stone care for urology teams. This advanced laser platform offers improved efficiency, versatility, and workflow for stone management and soft tissue procedures, featuring quiet operation and a smaller footprint. The system, available in Elyra™ and Elyra™ Plus configurations, has received positive feedback from initial clinical cases and expands BD's comprehensive portfolio for urologic stone management.

Becton, Dickinson and Company (BDX) reported a Q2 net loss of US$311 million despite sales of US$4,714 million, while also affirming full-year GAAP revenue growth guidance and appointing Peter Menziuso to lead BD Interventional. The company's investment narrative now focuses on executing in higher growth franchises like BD Interventional and addressing regulatory and quality pressures highlighted by a recent microbiology pouch recall. Despite these challenges, an expanded infection-prevention partnership and solid operational growth initiatives aim to stabilize earnings, though investors are urged to consider the impact of ongoing quality scrutiny on long-term growth.